Trial Profile
Phase II trial with abraxane and trastuzumab for advanced/recurrent HER2-positive breast cancer
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Jun 2013
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 25 Jun 2013 New trial record